230 related articles for article (PubMed ID: 30797720)
1. Comparative aspects of the care of familial hypercholesterolemia in the "Ten Countries Study".
Pang J; Chan DC; Hu M; Muir LA; Kwok S; Charng MJ; Florkowski CM; George PM; Lin J; Loi DD; Marais AD; Nawawi HM; Gonzalez-Santos LE; Su TC; Truong TH; Santos RD; Soran H; Tomlinson B; Yamashita S; Ademi Z; Watts GF
J Clin Lipidol; 2019; 13(2):287-300. PubMed ID: 30797720
[TBL] [Abstract][Full Text] [Related]
2. LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia.
Bogsrud MP; Græsdal A; Johansen D; Langslet G; Hovland A; Arnesen KE; Mundal LJ; Retterstøl K; Wium C; Holven KB
J Clin Lipidol; 2019; 13(2):279-286. PubMed ID: 30910667
[TBL] [Abstract][Full Text] [Related]
3. Women Living with Familial Hypercholesterolemia: Challenges and Considerations Surrounding Their Care.
Balla S; Ekpo EP; Wilemon KA; Knowles JW; Rodriguez F
Curr Atheroscler Rep; 2020 Aug; 22(10):60. PubMed ID: 32816232
[TBL] [Abstract][Full Text] [Related]
4. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T
Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
[TBL] [Abstract][Full Text] [Related]
5. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
; Vallejo-Vaz AJ; De Marco M; Stevens CAT; Akram A; Freiberger T; Hovingh GK; Kastelein JJP; Mata P; Raal FJ; Santos RD; Soran H; Watts GF; Abifadel M; Aguilar-Salinas CA; Al-Khnifsawi M; AlKindi FA; Alnouri F; Alonso R; Al-Rasadi K; Al-Sarraf A; Ashavaid TF; Binder CJ; Bogsrud MP; Bourbon M; Bruckert E; Chlebus K; Corral P; Descamps O; Durst R; Ezhov M; Fras Z; Genest J; Groselj U; Harada-Shiba M; Kayikcioglu M; Lalic K; Lam CSP; Latkovskis G; Laufs U; Liberopoulos E; Lin J; Maher V; Majano N; Marais AD; März W; Mirrakhimov E; Miserez AR; Mitchenko O; Nawawi HM; Nordestgaard BG; Paragh G; Petrulioniene Z; Pojskic B; Postadzhiyan A; Reda A; Reiner Ž; Sadoh WE; Sahebkar A; Shehab A; Shek AB; Stoll M; Su TC; Subramaniam T; Susekov AV; Symeonides P; Tilney M; Tomlinson B; Truong TH; Tselepis AD; Tybjærg-Hansen A; Vázquez-Cárdenas A; Viigimaa M; Vohnout B; Widén E; Yamashita S; Banach M; Gaita D; Jiang L; Nilsson L; Santos LE; Schunkert H; Tokgözoğlu L; Car J; Catapano AL; Ray KK;
Atherosclerosis; 2018 Oct; 277():234-255. PubMed ID: 30270054
[TBL] [Abstract][Full Text] [Related]
6. Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry.
Brunham LR; Ruel I; Khoury E; Hegele RA; Couture P; Bergeron J; Baass A; Dufour R; Francis GA; Cermakova L; Mancini GBJ; Brophy JM; Brisson D; Gaudet D; Genest J
Atherosclerosis; 2018 Oct; 277():419-424. PubMed ID: 30270080
[TBL] [Abstract][Full Text] [Related]
7. What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?
Kayikcioglu M; Tokgozoglu L; Dogan V; Ceyhan C; Tuncez A; Kutlu M; Onrat E; Alici G; Akbulut M; Celik A; Yesilbursa D; Sahin T; Sonmez A; Ozdogan O; Temizhan A; Kilic S; Bayram F; Sabuncu T; Coskun FY; Ildizli M; Durakoglugil E; Kirilmaz B; Yilmaz MB; Yigit Z; Yildirim AB; Gedikli O; Topcu S; Oğuz A; Demir M; Yenerçağ M; Yıldırır A; Demircan S; Yilmaz M; Kaynar LG; Aktan M; Durmus RB; Gokce C; Ozcebe Oİ; Akyol TK; Okutan H; Sag S; Gul OO; Salcioglu Z; Altunkeser BB; Kuku I; Yasar HY; Kurtoglu E; Kose MD; Demircioglu S; Pekkolay Z; Ilhan O; Can LH
Atherosclerosis; 2018 Oct; 277():341-346. PubMed ID: 30270069
[TBL] [Abstract][Full Text] [Related]
8. Familial hypercholesterolemia treatments: Guidelines and new therapies.
Raal FJ; Hovingh GK; Catapano AL
Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
[TBL] [Abstract][Full Text] [Related]
9. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
Miname MH; Santos RD
Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
[TBL] [Abstract][Full Text] [Related]
10. An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the "Ten Countries Study".
Pang J; Hu M; Lin J; Miida T; Nawawi HM; Park JE; Wu X; Ramli AS; Kim NT; Kwok S; Gonzalez-Santos LE; Su TC; Truong TH; Soran H; Yamashita S; Tomlinson B; Watts GF
BMJ Open; 2017 Oct; 7(10):e017817. PubMed ID: 29074516
[TBL] [Abstract][Full Text] [Related]
11. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
[TBL] [Abstract][Full Text] [Related]
12. International Developments in the Care of Familial Hypercholesterolemia: Where Now and Where to Next?
Pang J; Lansberg PJ; Watts GF
J Atheroscler Thromb; 2016 May; 23(5):505-19. PubMed ID: 26903443
[TBL] [Abstract][Full Text] [Related]
13. Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors.
Razek O; Cermakova L; Armani H; Lee T; Francis GA; Mancini GBJ; Frohlich J; Brunham LR
Can J Cardiol; 2018 Aug; 34(8):1004-1009. PubMed ID: 30056842
[TBL] [Abstract][Full Text] [Related]
14. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
Béliard S; Boccara F; Cariou B; Carrié A; Collet X; Farnier M; Ferrières J; Krempf M; Peretti N; Rabès JP; Varret M; Vimont A; Charrière S; Bruckert E;
Atherosclerosis; 2018 Oct; 277():334-340. PubMed ID: 30270068
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand.
Page MM; Ekinci EI; Burnett JR; Hooper AJ; Reid N; Bishop W; Florkowski CM; Scott R; O'Brien RC; Watts GF
J Clin Apher; 2021 Feb; 36(1):48-58. PubMed ID: 32911577
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.
Page MM; Stefanutti C; Sniderman A; Watts GF
Clin Sci (Lond); 2015 Jul; 129(1):63-79. PubMed ID: 25881720
[TBL] [Abstract][Full Text] [Related]
17. Familial Hypercholesterolemia in the Arabian Gulf Region: Clinical results of the Gulf FH Registry.
Alhabib KF; Al-Rasadi K; Almigbal TH; Batais MA; Al-Zakwani I; Al-Allaf FA; Al-Waili K; Zadjali F; Alghamdi M; Alnouri F; Awan Z; Kinsara AJ; AlQudaimi A; Almahmeed W; Sabbour H; Traina M; Atallah B; Al-Jarallah M; AlSarraf A; AlSayed N; Amin H; Altaradi H
PLoS One; 2021; 16(6):e0251560. PubMed ID: 34086694
[TBL] [Abstract][Full Text] [Related]
18. Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome.
Amor-Salamanca A; Castillo S; Gonzalez-Vioque E; Dominguez F; Quintana L; Lluís-Ganella C; Escudier JM; Ortega J; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
J Am Coll Cardiol; 2017 Oct; 70(14):1732-1740. PubMed ID: 28958330
[TBL] [Abstract][Full Text] [Related]
19. Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia.
Wang A; Richhariya A; Gandra SR; Calimlim B; Kim L; Quek RG; Nordyke RJ; Toth PP
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27385428
[TBL] [Abstract][Full Text] [Related]
20. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
